Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome.

Authors:
Dr Seng Cheng, PhD
Dr Seng Cheng, PhD
Genzyme, a Sanofi Company
Head of R&D, Rare Diseases Science
Framingham, MA | United States
Dr Seng H Cheng, PhD
Dr Seng H Cheng, PhD
SANOFI
Global Head of Research, Rare Disease
Framingham, MA | United States

Arterioscler Thromb Vasc Biol 2015 Apr 22;35(4):911-7. Epub 2015 Jan 22.

From the Department of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY (J.R.C., L.C., J.G., E.C., S.S., F.R.); and Genzyme, a Sanofi Company, Framingham, MA (N.P.C., C.A.N., S.H.C., B.M.W.).

Objective: Studies of mice with mild Marfan syndrome (MFS) have correlated the development of thoracic aortic aneurysm (TAA) with improper stimulation of noncanonical (Erk-mediated) TGFβ signaling by the angiotensin type I receptor (AT1r). This correlation was largely based on comparable TAA modifications by either systemic TGFβ neutralization or AT1r antagonism. However, subsequent investigations have called into question some key aspects of this mechanism of arterial disease in MFS. To resolve these controversial points, here we made a head-to-head comparison of the therapeutic benefits of TGFβ neutralization and AT1r antagonism in mice with progressively severe MFS (Fbn1(mgR/mgR) mice).

Approach And Results: Aneurysm growth, media degeneration, aortic levels of phosphorylated Erk and Smad proteins and the average survival of Fbn1(mgR/mgR) mice were compared after a ≈3-month-long treatment with placebo and either the AT1r antagonist losartan or the TGFβ-neutralizing antibody 1D11. In contrast to the beneficial effect of losartan, TGFβ neutralization either exacerbated or mitigated TAA formation depending on whether treatment was initiated before (postnatal day 16; P16) or after (P45) aneurysm formation, respectively. Biochemical evidence-related aneurysm growth with Erk-mediated AT1r signaling, and medial degeneration with TGFβ hyperactivity that was in part AT1r dependent. Importantly, P16-initiated treatment with losartan combined with P45-initiated administration of 1D11 prevented death of Fbn1(mgR/mgR) mice from ruptured TAA.

Conclusions: By demonstrating that promiscuous AT1r and TGFβ drive partially overlapping processes of arterial disease in MFS mice, our study argues for a therapeutic strategy against TAA that targets both signaling pathways although sparing the early protective role of TGFβ.

Download full-text PDF

Source
http://dx.doi.org/10.1161/ATVBAHA.114.305150DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376614PMC
April 2015
44 Reads
45 Citations
6.000 Impact Factor

Publication Analysis

Top Keywords

tgfβ neutralization
12
aortic aneurysm
8
arterial disease
8
aneurysm growth
8
at1r antagonism
8
neutralization at1r
8
disease mfs
8
marfan syndrome
8
fbn1mgr/mgr mice
8
at1r
7
tgfβ
7
mice
6
aneurysm
5
tgfβ-neutralizing antibody
4
antibody 1d11
4
contrast beneficial
4
1d11 contrast
4
losartan tgfβ-neutralizing
4
antagonist losartan
4
therapeutic benefits
4

References

(Supplied by CrossRef)

Similar Publications